RT Journal Article SR Electronic T1 Effects of Global O-GlcNAcylation on Galectin Gene-expression Profiles in Human Cancer Cell Lines JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 6691 OP 6697 DO 10.21873/anticanres.13037 VO 38 IS 12 A1 ALI A. SHERAZI A1 KOMAL A. JARIWALA A1 AMANDA N. CYBULSKI A1 JUSTIN W. LEWIS A1 JIM KARAGIANNIS A1 ROBERT C. CUMMING A1 ALEXANDER V. TIMOSHENKO YR 2018 UL http://ar.iiarjournals.org/content/38/12/6691.abstract AB Background/Aim: The effects of O-linked β-N-acetyl-D-glucosamine (O-GlcNAc) transferase (OGT) and O-GlcNAcase (OGA) inhibitors on galectin gene expression profiles were examined in MCF7, HT-29, and HL-60 cancer cell lines. Materials and Methods: Cell cultures were treated for 24 h with OGA inhibitor thiamet G or OGT inhibitor 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-5-thio-α-D-glucopyranose, and global O-GlcNAc levels and expression of galectin genes were determined using an immunodot blot assay and real-time quantitative polymerase chain reaction. Results: Two galectin genes, LGALS3 in MCF7 cells and LGALS12 in HL-60 cells, were up-regulated by O-GlcNAc, whereas other cell-specific galectins were unresponsive to changes in O-GlcNAc level. Of interest, basal levels of O-GlcNAc in resting HL-60 and HT-29 cells were significantly higher than those in cells differentiated into neutrophilic or enterocytic lineages, respectively. Conclusion: O-GlcNAc-mediated signaling pathways may be involved in regulating the expression of only a limited number of galectin genes. Additional O-GlcNAc-dependent mechanisms may work at the protein level (galectin secretion and intracellular localization) and warrant further investigation.